Liza Botros

Liza Botros

Auto-generated profile, based on publicly available information

Liza Botros

Centre for Human Drug Research Leiden The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
LBLiza Botros
Liza Botros
MPManon C. A. Pronk
Manon C. A. Pronk
JJJenny Juschten
Jenny Juschten
JLJohn Liddle
John Liddle
SMSofia K. S. H. Morsing
Sofia K. S. H. Morsing
JAJurjan Aman
Jurjan Aman
Aims: Endothelial barrier dysfunction leads to edema and vascular leak, carrying high morbidity and mortality. Previously, Abl kinase inhibition was shown to protect against vascular leak. Using the distinct inhibitory profiles of clinically available Abl kinase inhibitors, we aimed to provide a mechanistic basis for novel treatment strategies against vascular leakage syndromes. Methods & Results: Bosutinib most potently protected against inflammation-induced endothelial barrier disruption. In vivo, bosutinib prevented LPS-induced alveolar protein extravasation in an acute lung injury mice model. Mechanistically, Mitogen-activated Protein 4 Kinase 4 (MAP4K4) was identified as important novel mediator of endothelial permeability, which signals via ezrin, radixin and moesin proteins to increase turnover of integrin-based focal adhesions. The combined inhibition of MAP4K4 and Arg by bosutinib preserved adherens junction integrity and reduced turnover of focal adhesions, which synergistically act to stabilize the endothelial barrier during inflammation. Conclusion: MAP4K4 was identified as important regulator of endothelial barrier integrity, increasing focal adhesion turnover and disruption of cell-cell junctions during inflammation. Inhibiting both Arg and MAP4K4, the clinically available drug bosutinib may form a viable strategy against vascular leakage syndromes.

1 July 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LBLiza Botros
Liza Botros
RSRobert Szulcek
Robert Szulcek
Samara JansenSamara Jansen
Samara Jansen
KKKondababu Kurakula
Kondababu Kurakula
MGMarie-José Goumans
Marie-José Goumans
HBHarm-Jan Bogaard
Harm-Jan Bogaard

5 March 2021 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
DKDerek Jayantha Bandara Kleinveld
Derek Jayantha Bandara Kleinveld
LBLiza Botros
Liza Botros
MMM. Adrie W. Maas
M. Adrie W. Maas
JKJesper Kers
Jesper Kers
JAJurjan Aman
Jurjan Aman
NJNicole Juffermans
Nicole Juffermans
Background Trauma-induced shock is associated with endothelial dysfunction. We examined whether the tyrosine kinase inhibitor bosutinib as an adjunct therapy to a balanced blood component resuscitation strategy reduces trauma-induced endothelial permeability, thereby improving shock reversal and limiting transfusion requirements and organ failure in a rat polytrauma transfusion model. Methods Male Sprague–Dawley rats (n=13 per group) were traumatised and exsanguinated until a MAP of 40 mm Hg was reached, then randomised to two groups: red blood cells, plasma and platelets in a 1:1:1 ratio with either bosutinib or vehicle. Controls were randomised to sham (median laparotomy, no trauma) with bosutinib or vehicle. Organs were harvested for histology and wet/dry (W/D) weight ratio. Results Traumatic injury resulted in shock, with higher lactate levels compared with controls. In trauma-induced shock, the resuscitation volume needed to obtain a MAP of 60 mm Hg was lower in bosutinib-treated animals (2.8 [2.7–3.2] ml kg−1) compared with vehicle (6.1 [5.1–7.2] ml kg−1, P<0.001). Lactate levels in the bosutinib group were 2.9 [1.7–4.8] mM compared with 6.2 [3.1–14.1] mM in the vehicle group (P=0.06). Bosutinib compared with vehicle reduced lung vascular leakage (W/D ratio of 5.1 [4.6–5.3] vs 5.7 [5.4–6.0] (P=0.046) and lung injury scores (P=0.027). Conclusions Bosutinib as an adjunct therapy to a balanced transfusion strategy reduced resuscitation volume, improved shock reversal, and reduced vascular leak and organ injury in a rat polytrauma model.

1 June 2021 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
LBLiza Botros
Liza Botros
Samara JansenSamara Jansen
Samara Jansen
AAAli Ashek
Ali Ashek
OSOnno A. Spruijt
Onno A. Spruijt
JTJelco Tramper
Jelco Tramper
HBHarm-Jan Bogaard
Harm-Jan Bogaard
Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine (18FLT) positron emission tomography (PET) scanning was increased in pulmonary arterial hypertension patients, hence providing a possible biomarker for pulmonary arterial hypertension as it reflects vascular cell hyperproliferation in the lung. This study sought to validate 18FLT‐PET in an expanded cohort of pulmonary arterial hypertension patients in comparison to matched healthy controls and unaffected bone morphogenetic protein receptor type 2 mutation carriers. 18FLT‐PET scanning was performed in 21 pulmonary arterial hypertension patients (15 hereditary pulmonary arterial hypertension and 6 idiopathic pulmonary arterial hypertension), 11 unaffected mutation carriers and 9 healthy control subjects. In‐depth kinetic analysis indicated that there were no differences in lung 18FLT k3 phosphorylation among pulmonary arterial hypertension patients, unaffected bone morphogenetic protein receptor type 2 mutation carriers and healthy controls. Lung 18FLT uptake did not correlate with haemodynamic or clinical parameters in pulmonary arterial hypertension patients. Sequential 18FLT‐PET scanning in three patients demonstrated uneven regional distribution in 18FLT uptake by 3D parametric mapping of the lung, although this did not follow the clinical course of the patient. We did not detect significantly increased lung 18FLT uptake in pulmonary arterial hypertension patients, nor in the unaffected bone morphogenetic protein receptor type 2 mutation carriers, as compared to healthy subjects. The conflicting results with our preliminary human 18FLT report may be explained by a small sample size previously and we observed large variation of lung 18FLT signals between patients, challenging the application of 18FLT‐PET as a biomarker in the pulmonary arterial hypertension clinic.

15 November 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MRMarella Cornelia Elizabeth van Ruissen
Marella Cornelia Elizabeth van Ruissen
MDMenno van Diemen
Menno van Diemen
LBLiza Botros
Liza Botros
ITIngrid Tomljanovic
Ingrid Tomljanovic
HAHind Achbo
Hind Achbo
MMMatthijs Moerland
Matthijs Moerland
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials. This single‐center experimental study evaluated the intradermal lipopolysaccharide (id LPS) challenge model as a tool to induce and characterize vascular leakage in healthy participants. Eight participants (male:female = 4:4) received id LPS in the volar forearms, followed by serial pharmacodynamic assessments, including imaging and suction blister induction up to 9 hours after injection. Id LPS administration resulted in significant increases in skin perfusion ( P < 0.0001), erythema ( P = 0.0013), and skin volume ( P = 0.0008), indicating initial stages of inflammation and fluid extravasation. Blister fluid analysis revealed elevated extravascular concentrations of albumin ( P = 0.0011), total protein ( P < 0.0001), and neutrophils ( P = 0.0342), supporting the presence of vascular leakage. Moreover, the expression of endothelial activation markers VCAM‐1 ( P = 0.0015), ICAM‐1 ( P = 0.0004), ITGB1 ( P = 0.01), and E‐selectin ( P = 0.0218) increased significantly. Disruption of endothelial cell–cell integrity was supported by increased expression of VE‐cadherin ( P = 0.0002) in blister fluid. These findings support the applicability of the id LPS model for the induction of vascular leakage in humans. This model holds potential as a translational tool for evaluating the pharmacodynamic responses of vascular leakage‐targeting drugs in early clinical development.